JP6013184B2 - アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化 - Google Patents

アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化 Download PDF

Info

Publication number
JP6013184B2
JP6013184B2 JP2012532353A JP2012532353A JP6013184B2 JP 6013184 B2 JP6013184 B2 JP 6013184B2 JP 2012532353 A JP2012532353 A JP 2012532353A JP 2012532353 A JP2012532353 A JP 2012532353A JP 6013184 B2 JP6013184 B2 JP 6013184B2
Authority
JP
Japan
Prior art keywords
pkc
pkc isozyme
index
cells
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012532353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013506844A (ja
Inventor
カーン、タパン・クマー
アルコン、ダニエル・エル．
Original Assignee
ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート filed Critical ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート
Publication of JP2013506844A publication Critical patent/JP2013506844A/ja
Application granted granted Critical
Publication of JP6013184B2 publication Critical patent/JP6013184B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012532353A 2009-10-02 2010-10-01 アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化 Active JP6013184B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24836109P 2009-10-02 2009-10-02
US61/248,361 2009-10-02
PCT/US2010/051112 WO2011041670A2 (en) 2009-10-02 2010-10-01 Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016118888A Division JP2016197112A (ja) 2009-10-02 2016-06-15 アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化

Publications (2)

Publication Number Publication Date
JP2013506844A JP2013506844A (ja) 2013-02-28
JP6013184B2 true JP6013184B2 (ja) 2016-10-25

Family

ID=43302691

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012532353A Active JP6013184B2 (ja) 2009-10-02 2010-10-01 アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化
JP2016118888A Pending JP2016197112A (ja) 2009-10-02 2016-06-15 アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016118888A Pending JP2016197112A (ja) 2009-10-02 2016-06-15 アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化

Country Status (7)

Country Link
US (1) US20110212474A1 (enExample)
EP (1) EP2483695A2 (enExample)
JP (2) JP6013184B2 (enExample)
CN (1) CN102741696A (enExample)
BR (1) BR112012007557A2 (enExample)
CA (1) CA2776498A1 (enExample)
WO (1) WO2011041670A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145316A1 (en) * 2013-03-15 2014-09-18 Alkon Daniel L Methods for identifying neuroprotective pkc activators
EP3265810A1 (en) 2015-03-06 2018-01-10 Blanchette Rockefeller Neurosciences, Institute Methods for classifying populations including alzheimer's disease populations
EP3420363A1 (en) * 2016-02-22 2019-01-02 The West Virginia University Board of Governors on behalf of West Virginia University Diagnosing mild cognitive impairment (mci), predicting alzheimer's disease (ad) dementia onset, and screening and monitoring agents for treating mci or preventing dementia onset
US20180282784A1 (en) * 2017-03-31 2018-10-04 NeuroDiagnostics LLC LYMPHOCYTE-BASED PKCe TEST FOR ALZHEIMER'S DISEASE
CN115078570B (zh) * 2022-05-30 2024-05-28 郑州大学第一附属医院 Tau蛋白639位硫氰酸氨基酸修饰在快速质谱法检测阿尔茨海默症中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080784A (en) * 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US5976816A (en) * 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US20030108956A1 (en) * 1993-05-03 2003-06-12 Alkon Daniel L. Cell tests for Alzheimer's disease
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
AU2316797A (en) * 1996-02-29 1997-09-16 Mount Sinai Hospital Corporation Shc proteins
AU1630501A (en) * 1999-10-08 2001-04-23 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
AUPR215700A0 (en) * 2000-12-19 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid compound having cyclopropane ring
EP1358329A2 (en) * 2001-02-06 2003-11-05 Incyte Genomics, Inc. Lipid-associated molecules
ES2305234T3 (es) * 2001-02-27 2008-11-01 Blanchette Rockefeller Neurosciences Institute Diagnostico de la enfermedad de alzheimer basado en la fosforilacion de una proteina quinosa activada por mitogeno.
US20040014678A1 (en) * 2001-08-08 2004-01-22 Antonella Favit Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US6897014B2 (en) 2002-02-15 2005-05-24 Fuji Photo Film Co., Ltd. Silver halide photographic light-sensitive material, photographic emulsion, and mercapto group-containing polymer compound used for them
ITMI20031098A1 (it) * 2003-05-30 2004-11-30 Indena Spa Composti utili nella terapia del morbo di alzheimer e formulazioni che li contengono
KR100574017B1 (ko) 2003-08-11 2006-04-26 삼성전자주식회사 잉크젯 프린터의 잉크 카트리지
CN101223459A (zh) 2005-05-27 2008-07-16 卡尔蔡司Smt股份公司 光散射盘、其用途以及波阵面测量设备
WO2007016202A1 (en) * 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
US7595167B2 (en) * 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
WO2007044094A1 (en) * 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
US20090029873A1 (en) * 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
WO2008100449A2 (en) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury

Also Published As

Publication number Publication date
CA2776498A1 (en) 2011-04-07
US20110212474A1 (en) 2011-09-01
JP2016197112A (ja) 2016-11-24
WO2011041670A3 (en) 2011-06-30
BR112012007557A2 (pt) 2017-05-02
JP2013506844A (ja) 2013-02-28
EP2483695A2 (en) 2012-08-08
CN102741696A (zh) 2012-10-17
WO2011041670A2 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
Moses et al. Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease
JP2016197112A (ja) アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化
US20220236289A1 (en) Antibody array for measuring a panel of amyloids
Uberti et al. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients
ES2412268T3 (es) Alteraciones específicas de la Enfermedad de Alzheimer de la relación de fosforilación ERK1/ERK2 como biomarcadores moleculares específicos de la Enfermedad de Alzheimer (ADSMB)
US20210270847A1 (en) Protein and peptide biomarkers for traumatic injury to the central nervous system
US20200138951A1 (en) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
US20140018299A1 (en) Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury
JP2008520203A (ja) アルツハイマー病の診断および治療のためのホスファターゼ２ａ（ｐｐ２ａ）の異常
EP1934618B1 (en) Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
US20080076140A1 (en) Biomarkers of Alzheimer's Disease
Bhagavan et al. Restoration of TEA-induced calcium responses in fibroblasts from Alzheimer's disease patients by a PKC activator
RU2741227C1 (ru) Способ диагностики черепно-мозговой травмы с использованием белковых биомаркеров
RU2538644C1 (ru) Способ прогнозирования развития острого панкреатита после операций на органах брюшной полости
HK1171080A (en) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130924

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160921

R150 Certificate of patent or registration of utility model

Ref document number: 6013184

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250